Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dopamine Agonists and Impulse Control Disorders: A Complex Association
Marie Grall‐Bronnec, Caroline Victorri‐Vigneau, Yann Donnio, et al.
Drug Safety (2017) Vol. 41, Iss. 1, pp. 19-75
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Restless legs syndrome
Mauro Manconi, Diego García‐Borreguero, Barbara Schormair, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Closed Access | Times Cited: 156
Neurobiology of cue-reactivity, craving, and inhibitory control in non-substance addictive behaviors
Stephanie Antons, Matthias Brand, Marc N. Potenza
Journal of the Neurological Sciences (2020) Vol. 415, pp. 116952-116952
Closed Access | Times Cited: 106
Drug treatment strategies for depression in Parkinson disease
Melody Ryan, Courtney V. Eatmon, John T. Slevin
Expert Opinion on Pharmacotherapy (2019) Vol. 20, Iss. 11, pp. 1351-1363
Closed Access | Times Cited: 81
Cognitive effort and active inference
Thomas Parr, Emma Holmes, Karl Friston, et al.
Neuropsychologia (2023) Vol. 184, pp. 108562-108562
Open Access | Times Cited: 29
Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas
Adriana G. Ioachimescu, Maria Fleseriu, Andrew R. Hoffman, et al.
European Journal of Endocrinology (2018) Vol. 180, Iss. 1, pp. 31-40
Open Access | Times Cited: 72
The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review
Shivanee Nakum, Andrea E. Cavanna
Parkinsonism & Related Disorders (2016) Vol. 25, pp. 10-16
Open Access | Times Cited: 64
Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors
Sunita M. C. De Sousa, John Baranoff, R. Louise Rushworth, et al.
The Journal of Clinical Endocrinology & Metabolism (2019) Vol. 105, Iss. 3, pp. e108-e118
Open Access | Times Cited: 62
Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study
Sema Çiftçi Doğanşen, Uğur Çıkrıkçılı, Gonca Örük, et al.
The Journal of Clinical Endocrinology & Metabolism (2019) Vol. 104, Iss. 7, pp. 2527-2534
Open Access | Times Cited: 57
Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study
Mussa Almalki, Moayad A Alsuraikh, Eyad Almalki, et al.
Pituitary (2024) Vol. 27, Iss. 2, pp. 197-203
Closed Access | Times Cited: 7
Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review
Matthieu Béreau, Vanessa Fleury, Walid Bouthour, et al.
Revue Neurologique (2018) Vol. 174, Iss. 9, pp. 653-663
Closed Access | Times Cited: 58
Suicide in Parkinson’s disease
Melissa D. Shepard, Kate Perepezko, Martijn Broen, et al.
Journal of Neurology Neurosurgery & Psychiatry (2019) Vol. 90, Iss. 7, pp. 822-829
Open Access | Times Cited: 43
The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson’s disease
T. Celeste Napier, Alana Kirby, Amanda L. Persons
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 102, pp. 109942-109942
Closed Access | Times Cited: 42
Advances in understanding meso‐cortico‐limbic‐striatal systems mediating risky reward seeking
Patrick T. Piantadosi, Lindsay R. Halladay, Anna K. Radke, et al.
Journal of Neurochemistry (2021) Vol. 157, Iss. 5, pp. 1547-1571
Open Access | Times Cited: 35
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
Michele Fusaroli, Emanuel Raschi, Valentina Giunchi, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 9, pp. 727-736
Open Access | Times Cited: 26
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
Michele Fusaroli, Stefano Polizzi, Luca Menestrina, et al.
Drug Safety (2024) Vol. 47, Iss. 12, pp. 1275-1292
Open Access | Times Cited: 5
Neurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction
Zhenlei Peng, Qiyu Jia, Junxiong Mao, et al.
Frontiers in Psychiatry (2025) Vol. 15
Open Access
Treatment of Motor Symptoms of Parkinson’s Disease
Luca Marsili, Matteo Bologna, Lily Y. Chen, et al.
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 341-363
Closed Access
Autoagresja w teorii i praktyce psychologicznej
Sylwia Michałowska
Rozprawy i Studia - Uniwersytet Szczeciński (2025)
Closed Access
Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson’s Disease
Mark D. Latt, Simon J.G. Lewis, Olfat Zekry, et al.
Drugs & Aging (2019) Vol. 36, Iss. 3, pp. 189-202
Closed Access | Times Cited: 37
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Jing Liu, Fei Xu, Zhiyan Nie, et al.
Frontiers in Cellular and Infection Microbiology (2020) Vol. 10
Open Access | Times Cited: 37
D2/3Agonist during Learning Potentiates Cued Risky Choice
Leili Mortazavi, Tristan Hynes, Chloe S. Chernoff, et al.
Journal of Neuroscience (2023) Vol. 43, Iss. 6, pp. 979-992
Open Access | Times Cited: 10
Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study
Bernd Leplow, Daniela Renftle, Mareike Thomas, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 2, pp. 125-133
Open Access | Times Cited: 9
An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson’s disease
Amanda Scanga, Anne‐Louise Lafontaine, Marta Kamińska
Journal of Clinical Sleep Medicine (2023) Vol. 19, Iss. 6, pp. 1133-1144
Open Access | Times Cited: 9
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
Richard A. Feelders, Maria Fleseriu, Pınar Kadioğlu, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 9
Impulse control disorders in Parkinson’s disease
Ana Marqués, Franck Durif, Pierre‐Olivier Fernagut
Journal of Neural Transmission (2018) Vol. 125, Iss. 8, pp. 1299-1312
Closed Access | Times Cited: 29
Page 1 - Next Page

Scroll to top